Publication: Folic acid-conjugated cationic Ag2S quantum dots for optical imaging and selective doxorubicin delivery to HeLa cells
| dc.contributor.coauthor | Erkısa, Merve | |
| dc.contributor.coauthor | Arı, Ferda | |
| dc.contributor.coauthor | Ulukaya, Engin | |
| dc.contributor.department | Department of Chemistry | |
| dc.contributor.department | KUYTAM (Koç University Surface Science and Technology Center) | |
| dc.contributor.facultymember | Yes | |
| dc.contributor.kuauthor | Acar, Havva Funda Yağcı | |
| dc.contributor.kuauthor | Duman, Fatma Demir | |
| dc.contributor.kuauthor | Khodadust, Rouhollah | |
| dc.contributor.schoolcollegeinstitute | College of Sciences | |
| dc.contributor.schoolcollegeinstitute | Research Center | |
| dc.date.accessioned | 2024-11-10T00:05:15Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | We aim to develop folic acid ( FA)-conjugated cationic Ag2S near-infrared quantum dots (NIRQDs) for the delivery of doxorubicin (DOX) selectively to folate receptor (FR)-positive cancer cells to achieve enhanced drug efficacy and optical tracking in the NIR region. Materials & methods: Cationic Ag2S NIRQDs were decorated with FA using a PEG bridge and loaded with DOX. In vitro studies were performed on FR-positive human cervical carcinoma cells and FR-negative A549 cells. Results: Significantly higher uptake of DOX by human cervical carcinoma cells cells and a greater therapeutic effect along with a strong intracellular optical signal were obtained with DOX-loaded FA-conjugated Ag2S NIRQDs. Conclusion: These Ag2S NIRQDs are promising theranostic nanoparticles for receptor-mediated delivery of DOX with enhanced drug efficacy combined with optical imaging. | |
| dc.description.fulltext | No | |
| dc.description.harvestedfrom | Manual | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | Scopus | |
| dc.description.indexedby | PubMed | |
| dc.description.openaccess | NO | |
| dc.description.peerreviewstatus | N/A | |
| dc.description.publisherscope | International | |
| dc.description.readpublish | N/A | |
| dc.description.sponsoredbyTubitakEu | TÜBİTAK | |
| dc.description.sponsorship | Scientific and Technological Research Council of Türkiye (TÜBİTAK) [113Z164] | |
| dc.description.sponsorship | Uludağ University [BUAP(F)-2014/3] | |
| dc.description.studentonlypublication | No | |
| dc.description.studentpublication | Yes | |
| dc.description.version | N/A | |
| dc.identifier.WoSQuartile | Q2 | |
| dc.identifier.doi | 10.2217/nnm-2017-0180 | |
| dc.identifier.eissn | 1748-6963 | |
| dc.identifier.embargo | N/A | |
| dc.identifier.endpage | 2333 | |
| dc.identifier.grantno | 113Z164 | |
| dc.identifier.grantno | BUAP(F)-2014/3 | |
| dc.identifier.issn | 1743-5889 | |
| dc.identifier.issue | 19 | |
| dc.identifier.pubmed | 28875744 | |
| dc.identifier.scopus | 2-s2.0-85030166267 | |
| dc.identifier.startpage | 2319 | |
| dc.identifier.uri | https://doi.org/10.2217/nnm-2017-0180 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/16413 | |
| dc.identifier.volume | 12 | |
| dc.identifier.wos | 000411843400004 | |
| dc.keywords | Ag2S quantum dots | |
| dc.keywords | Cancer therapy | |
| dc.keywords | Doxorubicin | |
| dc.keywords | Near-infrared imaging | |
| dc.keywords | Targeting | |
| dc.language.iso | eng | |
| dc.publisher | Future Medicine | |
| dc.relation.affiliation | Koç University | |
| dc.relation.collection | Koç University Institutional Repository | |
| dc.relation.ispartof | Nanomedicine | |
| dc.relation.openaccess | N/A | |
| dc.rights | N/A | |
| dc.subject | Biotechnology | |
| dc.subject | Microbiology | |
| dc.subject | Nanoscience | |
| dc.subject | Nanotechnology | |
| dc.title | Folic acid-conjugated cationic Ag2S quantum dots for optical imaging and selective doxorubicin delivery to HeLa cells | |
| dc.type | Journal Article | |
| dspace.entity.type | Publication | |
| local.contributor.kuauthor | Duman, Fatma Demir | |
| local.contributor.kuauthor | Khodadust, Rouhollah | |
| local.contributor.kuauthor | Acar, Havva Funda Yağcı | |
| relation.isGoalOfPublication | a9786601-9431-4553-9a46-013bb366fb87 | |
| relation.isGoalOfPublication.latestForDiscovery | a9786601-9431-4553-9a46-013bb366fb87 | |
| relation.isOrgUnitOfPublication | 035d8150-86c9-4107-af16-a6f0a4d538eb | |
| relation.isOrgUnitOfPublication | d41f66ba-d7a4-4790-9f8f-a456c391209b | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 035d8150-86c9-4107-af16-a6f0a4d538eb | |
| relation.isParentOrgUnitOfPublication | af0395b0-7219-4165-a909-7016fa30932d | |
| relation.isParentOrgUnitOfPublication | d437580f-9309-4ecb-864a-4af58309d287 | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | af0395b0-7219-4165-a909-7016fa30932d |
